News

ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference

SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present…

1 year ago

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision…

1 year ago

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease

Topline data anticipated in Q2 2023NEW ORLEANS and LOS ANGELES and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics…

1 year ago

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy…

1 year ago

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence…

1 year ago

Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco

BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous…

1 year ago

AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma

AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approvalSINGAPORE and…

1 year ago

MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™…

1 year ago

Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders

Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader intellectual property portfolio now includes…

1 year ago

Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand

ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET Orion and Amneal enter strategic partnership – Orion receives exclusive…

1 year ago